Your search for rivaroxaban returned 148 results

Your search for rivaroxaban returned 148 results

Sort Results:

Relevant Recent
News

Xarelto Approved for Prevention of DVT

Janssen Pharmaceuticals announced FDA approval of Xarelto (rivaroxaban) tablets for the prevention of deep vein thrombosis (DVT) that may lead to a pulmonary embolism (PE) in people undergoing knee or hip replacement surgery.
News

No Clear Benefit for Rivaroxaban After Hospital Discharge

The researchers found that a composite outcome of symptomatic venous thromboembolism or death due to venous thromboembolism occurred in 0.83% of patients in the rivaroxaban group and in 1.10% in the placebo group (hazard ratio, 0.76; 95% confidence interval, 0.52 to 1.09; P=0.14).
ASH 2010

Issues in Thrombosis Management and Anticoagulation

Novel oral anticoagulants, that do not require the laboratory monitoring associated with warfarin therapy, may alter the landscape of venous thromboembolism treatment and stroke prevention in atrial fibrillation, according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.
Drugs in the Pipeline

First Results of Rivaroxaban for VTE Treatment in Active Cancer

Janssen and Bayer presented the first results from their comprehensive research program, CALLISTO, which evaluated rivaroxaban for the treatment and prevention of venous thromboembolism (VTE) in patients with active cancer, at the 2015 American Society of Hematology (ASH) Annual Meeting.
News

Rivaroxaban Tied to Lower Brain Bleed Risk in A-Fib

A once daily oral dose of rivaroxaban (Xarelto) significantly lowers the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) at moderate to high risk of stroke.
News

Food Type, Timing Has No Clinically Relevant Impact on Rivaroxaban

Currently, the prescribing information recommends 20mg once daily with an evening meal for the AF indication, and 15mg twice daily with food for 21 days, followed by 20mg once daily with food for the remainder of treatment for the DVT/PE indications.